- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
RFA, embolization protocol safely treats large fibroids
Reducing fibroid volume with radiofrequency ablation and then embolizing the fibroids is safe and feasible, according to a study presented at the 2005 RSNA meeting.
Reducing fibroid volume with radiofrequency ablation and then embolizing the fibroids is safe and feasible, according to a study presented at the 2005 RSNA meeting.
Dr. Hyun Kim and Jason Tsai of Johns Hopkins treated 22 symptomatic patients with large subserosal fibroids with RFA and uterine fibroid embolization. They used an RF probe up to 5 cm.
They achieved RFA target ablation size and temperature in 95.5% (21/22) of patients. A mean fibroid volume reduction of 49% was achieved (549 cc pretreatment versus 280.8 cc post-treatment). After one day, an MR scan in 10 patients showed no extra-uterine organ damage, as well as no infection, hemorrhagic complication, or fluid in pelvis or peritoneum. One patient developed delayed minimal drainage via RFA probe skin access, which resolved spontaneously over two days.
Follow-up at one year has revealed no significant morbidity, positive symptom severity scores, and few complications.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
